Biodesix(BDSX) - 2024 Q1 - Quarterly Results

i biodesix First quarter 2024 Total Revenue of $14.8 million, a year-over-year increase of 64%, and 7th consecutive quarter of >50% growth in Lung Diagnostic test volume; Raised $55 million in gross proceeds from an oversubscribed and upsized underwritten public offering of common stock and concurrent private placement in April 2024; LOUISVILLE, CO, May 8, 2024 – Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating re ...